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KEYPOINTS: 
1) FLT3ITD tyrosine kinase (TK) inhibition impairs glycolysis and glucose utilization 
without equally affecting glutamine metabolism 
2) Combined targeting of FLT3 TK activity and glutamine metabolism decreases 
FLT3ITD mutant cells leukemogenic potential in vitro and in vivo 
ABSTRACT 
FLT3 internal tandem duplication (FLT3ITD) are common mutations in acute myeloid 
leukemia (AML) associated with poor patient prognosis. Although new generation FLT3 
tyrosine kinase inhibitors (TKI) have shown promising results, the outcome of FLT3ITD AML 
patients remains poor and demands the identification of novel, specific and validated 
therapeutic targets for this highly aggressive AML subtype. Utilizing an unbiased genome-
wide CRISPR/Cas9 screen, we identify GLS, the first enzyme in glutamine metabolism, as 
synthetically lethal with FLT3-TKI treatment. Using complementary metabolomic and gene-
expression analysis, we demonstrate that glutamine metabolism, through its ability to 
support both mitochondrial function and cellular redox metabolism, becomes a metabolic 
dependency of FLT3ITD AML, specifically unmasked by FLT3-TKI treatment. We extend 
these findings to AML subtypes driven by other tyrosine kinase (TK) activating mutations, 
and validate the role of GLS as a clinically actionable therapeutic target in both primary AML 
and in vivo models. Our work highlights the role of metabolic adaptations as a resistance 
mechanism to several TKI, and suggests glutaminolysis as a therapeutically targetable 
vulnerability when combined with specific TKI in FLT3ITD and other TK activating mutation 
driven leukemias.  
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INTRODUCTION 
Acute myeloid leukemia (AML) is a highly heterogeneous disease at both the molecular and 
clinical level. Recent sequencing efforts have helped to categorize different subtypes based 
on their mutation profile and its putative effect on AML pathogenesis. Common subgroups 
include those carrying mutations in transcription factors and epigenetic regulators, cases 
carrying mutations in genes encoding for components of the spliceosome machinery and 
cohesin complexes, and those carrying mutations in signaling genes1,2. Within the last group, 
activating mutations of tyrosine kinases (TK) are the most frequent and generally predict for 
a poor outcome3. In particular, mutations in the type-III receptor TK FLT3 are present in 
about 30% of AML patients, are mostly secondary to an internal tandem duplication 
(FLT3ITD) of the juxtamembrane domain and predict for an increased relapse rate following 
standard therapies and a poor prognosis4. Although FLT3ITD mutations are acquired 
relatively late in leukemia evolution1,5 and are unable to produce an AML phenotype in 
animal models without collaborating mutations6, they are capable of conferring a state of 
oncogene addiction by activating survival pathways7. Their importance for the maintenance 
of the leukemic phenotype and as a relevant therapeutic target has also been confirmed by 
the results of a recent phase 3 randomized study (RATIFY), where a survival benefit for 
patients treated with FLT3 TK inhibitor (TKI) was demonstrated for the first time8, leading to 
recent FDA approval of the FLT3 inhibitor Midostaurin. However, despite our understanding 
of the role played by FLT3ITD mutations in AML and the rational design of targeted inhibitors 
of their TK activity, the overall outcome of AML patients carrying FLT3ITD mutations remains 
poor, suggesting that resistance mechanisms to targeted inhibitors might hinder the efficacy 
of these therapies9. Indeed mutations in the FLT3 TK domain have already been described 
as a frequent mechanism of resistance7. However, more recently, mutational analysis of 
patient samples obtained following relapse after FLT3-TKI treatment and a handful of 
preclinical studies have suggested that cellular adaptive mechanism might also play a role in 
FLT3-TKI resistance10-13 although these remain overall poorly defined.  
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FLT3ITD mutations are known to activate survival/proliferation signaling pathways, including 
the PI3-kinase/AKT, Ras/MAP kinase and JAK/STAT pathways14-17 that are also known to 
directly or indirectly alter cell metabolism18-20. As a result, leukemias harboring FLT3ITD 
mutations are often associated with a very proliferative and aggressive phenotype, high 
tumor bulk, and are accompanied by alterations in cellular metabolism to sustain this 
proliferative phenotype4,21.   
Metabolic reprogramming has emerged as a hallmark of transformed cells22 and several 
reports have recently highlighted the role of specific metabolic enzymes and metabolites in 
normal hematopoietic stem cell homeostasis and leukemogenesis through both direct effects 
on energy production, macromolecule biosynthesis, and their ability to modulate redox 
balance, epigenetic regulation, and signaling pathways23-29. Moreover, metabolism is able to 
rapidly respond to changing conditions within a cell, and it has already been shown, in both 
solid cancers and hematological malignancies, that metabolic adaptations, under therapeutic 
selective pressure, can act as key resistance mechanisms to standard therapeutics30,31. 
In this work, we aimed to identify novel cellular adaptive resistance mechanisms to FLT3-TKI 
treatment in FLT3ITD AML. Using several unbiased complementary approaches, we identify 
glutamine metabolism as a protective and adaptive response to FLT3-TKI, and describe the 
mechanisms underlying this phenotype. Finally, we validate glutaminolysis as a clinically 
actionable therapeutic vulnerability in both FLT3ITD and other AML subtypes carrying TK 
activating mutations, following TKI treatment.  
METHODS 
An extended methods section is available in the online supplemental Data. 
Cell culture 
MV411, MOLM13, THP1, K562 were cultured in RPMI1640 (Sigma) supplemented with 10% 
dialyzed fetal bovine serum (FBS) (Sigma) and 1% penicillin/streptomycin/glutamine. 
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Lineage depleted bone marrow cells from Rosa26Cas9/+, Flt3ITD/+ mice were transduced with 
retrovirus constructs pMSCV-MLL-AF9-IRES-YFP, pMSCV-MLL-AF4-PGK-puro and 
pMSCV-MLL-ENL-IRES-Neo and cultured in X-VIVO 20 (Lonza) supplemented with 10ng 
ml-1 IL3, 10ng ml-1 IL6 and 50ng ml-1 of SCF (Peprotech).  
Generation of genome-wide mutant libraries, CRISPR screening and gRNA 
competition assays 
CRISPR screens were performed using the previously reported WT Sanger genome-wide 
CRISPR library32. gRNA competition assays were performed using single and dual gRNA 
vectors as described previously32. The gRNA sequences are listed in supplemental Methods. 
Details are provided in supplemental Methods.  
Liquid chromatography coupled to mass spectrometry (LC-MS) for metabolomics 
analysis 
MV411 cells were plated at 0.5 x 106 cells per mL in media supplemented with uniformly-
labelled-13Carbon (U-13C6) glucose (11 mM) or uniformly-labelled-13Carbon, 15Nitrogen (U-
13C5,15N2) glutamine (2 mM) (Cambridge Isotope laboratories) for 48 h before sampling. 
Details of metabolite extraction and LC-MS analysis are provided in supplemental Methods. 
Adult Primary Leukaemia and Cord Blood Samples Drug and Proliferation Assays 
Human AML MNC were obtained from bone marrow or peripheral blood of patients. Normal 
CD34 samples were obtained from leukapheresis products of myeloma/lymphoma patients 
in bone marrow remission. Informed consent was obtained in accordance with the 
Declaration of Helsinki and the study was conducted under local ethical approval (REC 07-
MRE05-44). Culture condition for methylcellulose and liquid culture assay of primary 
samples are as previously described33. 
In vivo experiments 
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MV411 cells transduced with control “Scramble” shRNA or GLS shRNA  were transplanted 
(3x106) into sublethally irradiated (2 Gy) 8-12 weeks old NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) male mice, via tail vein injection. Three days following transplant, mice were 
fed a doxycycline diet (1g/kg) to induce the shRNA and following disease dissemination 
treatment was started.  Mice were treated by gavage either with vehicle (22% hydroxypropyl-
β-cyclodextrin/0.3% DMSO) or AC220 at 1 mg/kg daily for 8 days and then 0.1mg/kg till they 
succumbed to disease. Survival was measured as the time from transplantation until the 
point at which mice had to be humanely culled due to overt clinical symptoms typical of the 
MV411 xenotransplant model34.  
RESULTS 
A genome-wide CRISPR/Cas9 screen identifies GLS as a synthetic lethal gene in TKI 
treated FLT3ITD cells 
In order to identify genes and pathways that would sensitize FLT3ITD AML to FLT3-TKI 
treatment in an unbiased manner, we performed a genome-wide CRISPR/Cas9 synthetic 
lethality screen in the FLT3ITD cell line MOLM13 during treatment with the highly potent and 
specific FLT3ITD inhibitor AC220 (quizartinib), that is currently being assessed in phase 3 
clinical trials34 or vehicle control (Figure 1A). A total of 304 genes dropped out following 
AC220 treatment (defined as genes showing a drop out of ≤ 0.5 log2 fold change in at least 
80% of gRNA at false discovery rate <0.01) (Supplemental Table 1). KEGG gene set 
enrichment analysis, using Enrichr software35,36, demonstrated significant enrichment for 
genes involved in several pathways, including some obviously relevant to AML biology 
(highlighted in the figure). Amongst these, metabolic pathways, including mostly genes 
involved in oxidative phosphorylation and the tricarboxylic acid (TCA) cycle were significantly 
enriched (Figure 1B). Amongst the top metabolic genes depleted following AC220 treatment, 
glutaminase (GLS) demonstrated the highest number of significantly depleted gRNA (all 5 
guides out of 5 targeting the gene), indicating a strong synthetic lethal interaction with 
AC220 (Figure 1C-D). GLS is the first enzyme in glutamine catabolism, a metabolic pathway 
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with well-established anaplerotic and biosynthetic roles in cancer cells37 which also regulates 
the availability of substrates for both the TCA cycle and oxidative phosphorylation, two of the 
most affected pathways in our screen. Importantly, a potent and selective GLS inhibitor 
CB839 is currently being investigated in clinical trials38. Given the strong synthetic lethal 
interaction in the screen, its central role in regulating metabolic pathways shown to be 
affected in our screen and the availability of a clinical grade inhibitor, we decided to further 
investigate the role of GLS as a clinically relevant synthetic lethal pair in AC220-treated 
FLT3ITD cells.  
In single targeting experiments, GLS was validated as synthetically lethal with AC220 in 
human and murine FLT3ITD mutant, but not in wild-type FLT3 (FLT3wt) cells (Figure 1E-G and 
Supplemental Figure 1A-C). Moreover, the genetic ablation of GLS was non-toxic in 
untreated FLT3ITD cells (Supplemental Figure 1D-F). We then confirmed that the silencing of 
GLS by short hairpin RNA (shRNA) and its chemical inhibition using the specific clinical 
grade inhibitor CB839 at concentrations shown to be inhibiting GLS enzymatic activity in a 
specific fashion38, produced similar effects on cell proliferation when combined with AC220 
in FLT3ITD-mutant cells, and the combination treatment induced higher levels of apoptosis 
compared to AC220 treatment alone in FLT3ITD, but not FLT3wt cells (Figure 1H-K and 
Supplemental Figure 1G-K). In line with these findings, glutamine starvation sensitized 
FLT3ITD cells to AC220, while having negligible effects in untreated cells (Figure 1L-M). 
Taken together, these data demonstrate that glutamine metabolism represents a metabolic 
dependency in FLT3ITD cells that is only unmasked by FLT3-TKI, making genetic and 
chemical inhibition of GLS a feasible strategy to sensitize these cells to AC220. 
FLT3 tyrosine kinase inhibition markedly reduces glycolysis without affecting 
glutamine uptake in FLT3ITD cells 
Previous studies have demonstrated that cells carrying FLT3ITD display a highly glycolytic 
phenotype and enhanced central carbon metabolism21. Indeed, gene set enrichment 
analysis (GSEA)39,40 of published gene expression datasets of untreated AML patients at 
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diagnosis1,41,42, demonstrate that signatures involving glucose metabolism, TCA cycle, and 
electron transport chain (ETC) are consistently upregulated in FLT3ITD compared to FLT3wt 
samples across all datasets analyzed (Supplemental Figure 2A-D). Furthermore, murine 
bone marrow (BM) cells carrying FLT3ITD demonstrate both increased glycolytic 
activity/capacity and oxygen consumption compared to their FLT3wt counterpart 
(Supplemental Figure 2E-F). Considering that glucose and glutamine are the main fuels for 
central carbon metabolism in cultured cells37,43, we investigated the effects of FLT3-TKI on 
the utilization of these nutrients and on central carbon metabolism. Dynamic measurement 
of the concentration of glucose and glutamine in FLT3ITD cell-conditioned medium confirmed 
that, whilst glucose uptake was almost completely blocked during treatment with AC220, 
glutamine uptake was only modestly reduced and by 48 hours it was not significantly 
different between treated and untreated cells (Figure 2A-D). Liquid chromatography-mass 
spectrometry (LC-MS) analysis using U-13C6-glucose confirmed a marked reduction in 
glucose labelling of glycolytic intermediates/products upon FLT3 TK inhibition in FLT3ITD 
mutant cells (Figure 2E and Supplemental Table 2). The effects of AC220 on glycolysis were 
further confirmed by time-resolved metabolic profiling (Figure 2F-G). As might be expected 
based on the profound antiproliferative effects of AC220 in the same cells (Supplemental 
Figure 3A-B), a reduction in total levels of most TCA cycle intermediates was also observed 
but this was less pronounced and the presence of 13C2 citrate and 13C3 aspartate 
isotopologues – products, respectively, of the activity of  the anaplerotic enzymes pyruvate 
dehydrogenase (PDH) and pyruvate carboxylase (PC) - suggests that anaplerotic oxidative 
metabolism is still active in these cells (Figure 2H-I and Supplemental Table 2). Moreover, 
the preservation of the unlabeled (13C0) and partially labelled (13C2) fractions of TCA cycle 
intermediates also suggests that alternative carbon sources, such as glutamine, were 
utilized by the cells to support the production of TCA cycle metabolites following AC220 
treatment (Figure 2H and Supplemental Table 2). Gene-expression studies, performed prior 
to the induction of significant levels of apoptosis by AC220, confirmed the more pronounced 
effects of FLT3 inhibition on glycolytic enzymes compared to TCA cycle and anaplerotic 
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genes including glutaminolytic enzymes, GLS and glutamate dehydrogenase 1 (GLUD1) 
(Figure 2J-M, Supplemental Figure 3C-D and Supplemental Table 3). Overall these data 
highlight that FLT3 inhibition significantly impairs the utilization of glucose as a carbon 
source and particularly glycolysis in FLT3ITD cells, whereas glutamine utilization and 
anaplerotic oxidative metabolism via the TCA cycle were not equally affected.  
Glutamine supports the TCA cycle and glutathione production following FLT3 
inhibition 
In order to understand the fate of glutamine metabolism in FLT3ITD cells following AC220 
treatment, we performed LC-MS analysis upon incubation with stable isotope labelled 
glutamine (U-13C5,15N2-glutamine). Intracellular levels of labelled glutamine were increased in 
treated cells, confirming that glutamine uptake was not impaired in these cells but, as 
expected, given the antiproliferative effects of AC220, incorporation of labelled glutamine in 
TCA cycle intermediates was reduced and overall the level of most TCA cycle intermediates 
was decreased compared to vehicle treated cells. However, between 20-40% of the total 
pool of TCA cycle intermediates was still labelled from glutamine oxidative metabolism in 
AC220-treated cells compared to 30-60% in vehicle treated cells, suggesting that despite a 
significant reduction in overall TCA cycle activity, glutamine is still a major anaplerotic 
substrate in FLT3-TKI treated cells (Figure 3A-B and Supplemental Table 2). Of note, AC220 
treated cells were still able to produce aspartate (Figure 3A), a readout of ETC activity44,45, 
indicating that their respiratory function was not compromised by FLT3-TKI treatment (total 
levels of aspartate were actually increased, possibly reflecting lack of utilization due to FLT3-
TKI antiproliferative effects). Consistent with this hypothesis, AC220-treated cells increased 
their mitochondrial membrane potential and showed a trend towards increased mitochondrial 
mass (Figure 3C-D and Supplemental Figure 4A). We did not observe any significant 
contribution from glutamine reductive metabolism in FLT3ITD mutant cells and this did not 
change following AC220 treatment (Supplemental Figure 4B) 
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In addition to supporting TCA cycle activity, glutamine, via glutamate, is also a precursor of 
glutathione, the major cellular anti-oxidant46. Of note, the reduced/oxidized glutathione ratio 
(GSH/GSSG) was generally preserved in AC220 treated cells (Figure 3E), and glutathione 
metabolism genes, including the master regulator of antioxidant response NFE2L2, were not 
affected by AC220 treatment in FLT3ITD mutant cells (Supplemental Figure 4C-D and 
Supplemental Table 3). As our labelling experiments showed that glutamine largely 
contributes to glutamate and GSH generation (Figure 3A, F), we hypothesized that 
glutamine metabolism might play a role in maintaining redox homeostasis in AC220 treated 
cells. Consistent with this hypothesis, glutamine starvation markedly reduced GSH levels in 
AC220 treated cells and these effects correlated with a significant increase in intracellular 
reactive oxygen species (ROS) levels (Figure 3G-H and Supplemental Figure 4E). Overall 
these data suggest a role for glutamine metabolism in supporting both mitochondrial function 
and redox homeostasis in FLT3ITD cells under the cellular stress of TK inhibition. 
The effects of combined FLT3-TKI and GLS inhibitor treatment can be rescued by the 
glutamine downstream product α-ketoglutarate  
In order to clarify the relative importance of the metabolic pathways supported by glutamine 
in the survival of FLT3ITD cells upon TKI treatment, we specifically targeted both glutathione 
metabolism and respiratory function using respectively buthionine sulfoximine (BSO), an 
inhibitor of GSH synthesis47, or phenformin, an ETC (Complex I) inhibitor 44 in addition to 
AC220. However, neither of the two combinations was able to fully phenocopy the effects of 
glutamine starvation or GLS inhibition (Supplemental figure 5A-B). We also failed to 
completely rescue the effects of glutamine starvation or GLS inhibition using the antioxidant 
N-acetylcysteine (NAC) or anaplerotic substrates such as pyruvate or aspartate 
(Supplemental Figure 5C-H). These data support a model whereby both branches of 
glutamine metabolism, supporting TCA cycle/mitochondrial function and GSH synthesis, are 
important for continued cell survival and blocking only one of these branches is insufficient to 
recapitulate the effects of glutamine starvation or GLS inhibition.  
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To confirm this hypothesis, we used a cell permeable form of α-ketoglutarate (αKG), a 
downstream metabolic product of glutamine metabolism, to rescue the effects of combined 
AC220 and CB839 treatment in FLT3ITD cells. Amongst other functions48, αKG supports both 
the TCA cycle and glutamate production and can therefore rescue both branches of 
glutamine metabolism. Moreover, αKG is known to regulate redox homeostasis in cancer 
cells49.  Treatment of FLT3ITD cells with combined AC220 and CB839 resulted in reduced 
oxygen consumption, during both basal and maximal respiration, and increased intracellular 
ROS production compared to single agent alone. However, these effects were rescued by 
concomitant treatment with αKG, in keeping with its anaplerotic and antioxidant properties 
(Figure 4A-D). The salvage of the metabolic phenotype correlated with a complete rescue of 
the additional cell death related to the combination treatment by αKG (Figure 4E-F). Overall, 
these data further confirm the importance of glutamine metabolism in supporting both TCA 
cycle and redox metabolism in FLT3ITD cells treated with AC220. 
The effects of combined GLS and TKI extend to other TK activating mutations, 
primary AML samples and in vivo models 
To determine if a similar rewiring of metabolism occurs in leukemia driven by other activated 
TK that are amenable to targeted inhibition, we analyzed the metabolic consequences of 
inhibiting the chimeric BCR-ABL tyrosine kinase, which is central to the pathogenesis of 
chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic 
leukaemia 50, using its specific inhibitor imatinib51. Indeed, in a BCR-ABL positive cell line, 
imatinib treatment resulted in a reduction of glycolytic activity that also correlated with a 
decrease in gene expression levels of glycolytic enzymes (Figure 5A-C). Conversely, the 
effects on TCA cycle and glutathione metabolism genes were much less pronounced and 
although a significant reduction in both GLS and GLUD1 gene expression levels were noted 
following imatinib treatment, this was less than 50% and much smaller than those observed 
on glycolytic genes (Supplemental Figure 6A-C and Supplemental table 3). As observed in 
FLT3ITD cells, combining imatinib with CB839 led to increased apoptosis of BCR-ABL 
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positive cells, which correlated with enhanced intracellular ROS production and reduced 
oxygen consumption. Moreover, as with FLT3ITD AML, these effects could also be fully 
rescued by αKG (Figure 5D-F).  
Finally, we sought to confirm our findings in more physiological and clinically relevant 
models. Using primary AML samples from patients carrying a FLT3ITD mutation, we found 
that AC220 treatment led to a reduction in glycolytic capacity, and combined treatment with 
AC220 and CB839 led to a reduction in basal oxygen consumption (Figure 6A-B). These 
effects correlated with a further reduction in the viability of FLT3ITD primary samples following 
combined treatment that appeared proportional to the levels of FLT3 mutation, as measured 
by variant allele frequency (VAF), in each sample while similar effects were not observed in 
FLT3wt samples (Figure 6C and Supplemental Figure 7A-B). The combined treatment also 
led to reduced colony-forming-cell (CFC) output in BM murine cells and AML primary 
samples carrying FLT3ITD mutations while similar effects were not observed in normal CD34+ 
samples or FLT3wt AML patient samples, suggesting that these effects are specific to 
FLT3ITD cells (Supplemental Figure 7C-F). Finally, we tested the effects of combined GLS 
and FLT3 TK inhibition in vivo using FLT3ITD MV411 cells stably expressing a doxycycline 
inducible GLS or scrambled shRNA alongside a red fluorescent protein (RFP) reporter to 
allow tracking of shRNA expression. We transplanted shRNA GLS or scrambled cells into 
recipient immunocompromised mice, allowed leukemia to develop, at which point we fed 
mice with a doxycycline containing diet and also initiated AC220 treatment by oral gavage. 
MV411 generated leukemia are extremely aggressive but also highly sensitive to FLT3 
inhibitor treatment34 (data not shown). Using a low dose of AC220 in combination with a 
doxycycline containing diet all mice succumbed to disease while on treatment. However, 
despite the very aggressive nature of this leukemia, mice transplanted with cells carrying 
shRNA targeting GLS showed a modest but statistically significant increase in survival 
compared to mice transplanted with control cells (Figure 6D). We also observed that the 
mice transplanted with shRNA targeting GLS had lower levels of disease burden in bone 
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marrow and spleen (as measured by percentage of RFP positive cell within human CD45 
cells) and a trend towards smaller spleen size (Figure 6E-F and Supplemental Fig 7G). 
Finally GLS depletion was measured in vivo from human cells isolated from mouse organs. 
Interestingly, in the shRNA GLS transduced cells, AC220 treatment resulted in a 50% 
reduction in GLS knockdown efficiency suggesting preferential killing of cells having lower 
levels of GLS expression (Supplemental Figure 7H). 
DISCUSSION 
In this study we used orthogonal unbiased approaches including CRISPR/Cas9 synthetic 
lethality screen, metabolomics and gene expression analysis, to reveal that FLT3ITD cells 
develop a metabolic dependency on glutamine metabolism following FLT3 TK inhibition. 
Targeted inhibition of FLT3 TK activity appears to suppress the enhanced central carbon 
metabolism typical of FLT3ITD cells by mostly hindering glucose uptake and utilization thus 
predominantly reversing the glycolytic phenotype. However, TCA cycle activity and 
respiratory function, although reduced, are less affected and are supported by continuous 
uptake of glutamine, the other main fuel for central carbon metabolism. Combined 
suppression of FLT3 TK activity and glutamine metabolism using both GLS chemical 
inhibition and gene silencing, leads to an increased cell death in FLT3ITD cells, including 
models previously shown to be already highly sensitive to FLT3 TK inhibition. We also 
extend these findings to a model of leukemia carrying BCR-ABL TK activating mutations, 
primary AML samples and in vivo models. We demonstrate that glutamine metabolism 
supports both the TCA cycle and redox metabolism upon FLT3 TK inhibition and, through 
rescue experiments, we further validate the role of all these branches of glutamine 
metabolism in cellular survival (Figure 6G). Our data expand the findings of a recent report 
on the activity of combined GLS and FLT3 TK inhibition in FLT3ITD AML by providing in depth 
mechanistic explanation for these findings and extending their validity to primary AML 
samples and other TK activating mutated leukemias52. Moreover they also explain 
mechanistically previous published observations suggesting that combined targeting of FLT3 
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TK activity and redox metabolism or ETC might enhance toxicity in FLT3 mutated AML53,54. 
However, it is entirely plausible that another consequence of glutamine metabolism might 
also underlie, at least in part, the effects of targeting it. For instance, branched chain amino 
acids, produced by the transamination of glutamine derived glutamate, have recently been 
shown to support the maintenance and progression of myeloid leukemias27.  
GLS has recently emerged as a therapeutic target in both solid and hematological 
malignancies and potent GLS inhibitors, including the one used in this study, have now 
entered clinical trials in several malignancies [NCT02071862 and NCT02071927]. GLS is the 
most abundant isoform present in hematopoietic cells and has already been suggested as a 
potential therapeutic target in AML55. However, our data show that specifically in FLT3ITD 
mutated AML, GLS inhibition, on its own, produces only mild antiproliferative effects and only 
becomes a metabolic vulnerability following FLT3 TK inhibition, with similar effects not 
observed in normal cells or leukemic cells that lack TK activating mutations. Our results 
therefore suggest a therapeutic window for this combination therapy and confirm its 
specificity and potential utility in several TK mutated leukemias.  
Of note, the best effects in combination with FLT3 TK inhibition were observed when FLT3ITD 
cells were starved of glutamine rather than following GLS inhibition. This suggests that 
FLT3ITD mutated cells might also rely on ancillary pathways of glutamine metabolism 
releasing its γ-nitrogen and producing glutamate. Moreover, glutamine γ-nitrogen is a central 
substrate for the biosynthesis of nucleotides, NAD, amino acids and glucosamine-6-
phosphate56, and given that this function is not targeted by GLS inhibition, it is also plausible 
that these glutamine dependent metabolic pathways support cell survival following AC220 
and combination treatment.  
The ability of FLT3-TKI to predominantly revert the glycolytic phenotype, while having a less 
pronounced effect on TCA cycle activity and oxidative metabolism is another important 
observation stemming from this work. With regards to this it is noteworthy that, consistent 
with our findings, two recent reports have suggested that both AML and CML therapy-
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resistant cells display increased mitochondrial mass and a high oxidative phosphorylation 
status which is therapeutically actionable57,58. However, the exact mechanisms whereby 
some metabolic phenotypes are particularly dependent on FLT3 TK activity and how the 
described metabolic adaptations are established remains unknown and these fundamental 
questions merit further studies. Speculatively the ability of FLT3 TK to control glycolysis 
could be explained by its activation of AKT17 which can modulate  transcription factors, such 
as FOXO, known to regulate glycolysis59 or directly control the activity of several glycolytic 
enzymes21,60,61. However an improved understanding of the molecular mechanisms leading 
to this metabolic phenotype and whether other anaplerotic substrates, such as fatty acids, 
also contribute to oxidative phosphorylation in therapy resistant cells might help to clarify the 
basis of resistance and help target it more effectively.   
In conclusion, our results highlight the importance of FLT3 mutations and downstream 
signaling in the control of leukemia cell metabolism, extend our understanding of the role of 
metabolic adaptations in the resistance to treatment with FLT3 and other TK inhibitors and 
provide an example of a complementary unbiased approach to study the role of metabolism 
in leukemia and as a tool for the design of novel and specific therapeutic strategies targeting 
cell metabolism in AML. 
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FIGURE LEGENDS 
Figure 1: GLS gene deletion and chemical inhibition are synthetically lethal with FLT3 
tyrosine kinase inhibitors 
(A) Schematic of the genome-wide CRISPR/Cas9 synthetic lethality screen in the FLT3ITD 
mutant cell line MOLM13. (B) KEGG pathways enrichment analysis of drop-out genes from 
CRISPR/Cas9 screen sorted by combined score calculated using Enrichr software35,36. 
Pathways relevant to AML biology are highlighted while the remaining are grayed out. (C) 
List of top ten genes from the “metabolic pathways” gene list sorted according to average 
fold depletion from gRNAs. (D) Bar graph depicting individual fold depletion for each gRNA 
targeting GLS. (E-G) Growth inhibition curves to AC220 of MOLM13 (E) and murine bone 
marrow cells expressing MLL/AF9-FLT3ITD (F) and MLL/AF9 (G) transduced respectively 
with “empty” gRNA control or 2 different gRNA targeting GLS  (mean ± s.e.m., n=3, P<0.001 
for treatment effect comparing control and both Gls knockout for E and F, ns, not significant 
for G, two-way ANOVA). (H-I) Apoptosis in the FLT3ITD mutant cell lines MV411 (H) and 
MOLM13 (I) transduced with control “Scramble” shRNA and GLS shRNA following treatment 
with AC220 0.5nM for 48hrs (for MV411 mean ± s.e.m., n=7, **** P<0.0001, ** P=0.0086, for 
MOLM13 mean ± s.e.m., n=3, ** P=0.0014 for AC220 treatments comparison between 
Scramble and GLS shRNA, ** P=0.0050 for DMSO versus AC220 comparison in the 
scramble shRNA, two-way ANOVA with Bonferroni’s multiple comparisons). (J-K) Apoptosis 
in MV411 (J) and MOLM13 (K) following treatment with AC220 1nM, CB839 100nM or their 
combination (for MV411 mean ± s.e.m., n=14, ** P=0.0033, **** P<0.0001, for MOLM13 
mean ± s.e.m., n=16, * P=0.0126,*** P=0.0003, ANOVA with Tukey’s multiple comparisons). 
(L-M) Apoptosis in MV411 (L) and MOLM13 (M) grown in the presence (full media) or 
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absence of glutamine following treatment with AC220 1nM for 48hrs (for MV411 mean ± 
s.e.m., n=24, for MOLM13 mean ± s.e.m., n=11, **** P<0.0001, *** P=0.0007, two-way 
ANOVA with Bonferroni’s multiple comparisons). (s.e.m., standard error of mean). 
Figure 2: FLT3 tyrosine kinase inhibition reduces glucose uptake and central carbon 
metabolism without affecting glutamine uptake 
(A-D) Time-course analysis of glucose and glutamine uptake from media by MV411 (A-B) 
and MOLM13 (C-D) cells treated with AC220 1 nM or vehicle control (mean ± s.e.m., n=3, 
**** P<0.0001, two-way ANOVA with Bonferroni’s multiple comparisons). (E) Total and 
isotopologue abundance of selected glycolytic intermediates and products measured by 
liquid chromatography-mass spectrometry (LC-MS) analysis in MV411 cell extracts treated 
with AC220 1nM or vehicle control and grown in media containing uniformly-labelled-
13Carbon [U-13C6] glucose (GLC) (mean ± s.e.m., n=5, *** P=0.0004 for total 3-
Phosphoglycerate and P=0.0007 for total lactate, two-tailed paired t-test). (F-G) Extracellular 
acidification rate (ECAR) of MV411 (F) and MOLM13 (G) cells treated with AC220 1nM or 
vehicle control (mean ± s.e.m., n=3, **** P<0.0001, *** P=0.0003, two-way ANOVA with 
Bonferroni’s multiple comparisons). (H) Total and isotopologue levels of selected TCA cycle 
intermediates in MV411 cells  treated as in (E) (mean ± s.e.m., n=5, *** 
P=0.0009,**P=0.0011, ns, not significant, two-tailed paired t-test). (I) Percentage of total 
levels of citrate and aspartate provided respectively by 13C2 and 13C3 fraction following AC220 
treatment as in (E) (mean ± s.e.m., n=5, **** P<0.0001, ns, not significant, two-way ANOVA 
with Bonferroni’s multiple comparisons). (J-K) Volcano plot for gene expression changes by 
RNA-sequencing (n=2 for each cell line) of MV411 and MOLM13 cells treated with AC220 1 
nM compared to vehicle control highlighting reduced expression of glycolysis genes (top 
panels) and the minimal effects on TCA cycle genes (bottom panels). (L-M) q-PCR validation 
in MV411 (L) and MOLM13 (M) for the reduced expression of lactate dehydrogenase, LDHA  
and glucose transporter, GLUT3 following treatment with AC220 1nM (top panels) (mean ± 
s.e.m., MV411 n=4, MOLM13 n=5, for LDHA ** P=0.0053, *** P=0.0005, for GLUT3, MV411 
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* P=0.0150, MOLM13, * P=0.0387, two-tailed paired t-test) and for the lack of changes in 
expression in glutamine metabolism genes GLS and glutamate dehydrogenase, GLUD1 
(bottom panels) (mean ± s.e.m., n=4, ns, not significant by two-tailed paired t-test). 
Figure 3: Glutamine supports both mitochondrial function and glutathione production 
following FLT3 tyrosine kinase inhibition  
(A) Total and isotopologue levels of TCA cycle intermediates, glutamate and reduced 
glutathione (GSH) measured by LC-MS analysis in MV411 cells  treated with AC220 1 nM or 
vehicle control and grown in media containing U-13C5 and 15Nitrogen [15N2] glutamine (GLN) 
(mean ± s.e.m., n=5, *** P=0.0005, ** P=0.0017, * P=0.0195 for citrate, P=0.0228 for malate, 
P=0.0216 for glutamate, ns, not significant, two-tailed paired t-test). A schematic 
representation of glutamine metabolism and labelling pattern of metabolites by is also 
provided. (B) Percentage of total levels of TCA cycle metabolites labelled by U-13C5,15N2-
GLN through its oxidative metabolism measured by LC-MS analysis in MV411 cells treated 
with AC220 1 nM or vehicle control (mean ± s.e.m., n=5, **** P<0.0001, *** P=0.0008, ** 
P=0.0067, two-way ANOVA with Bonferroni’s multiple comparisons). (C) Relative 
mitochondrial membrane potential of MV411 cells treated with AC220 1 nM or vehicle control 
(left panel) with representative flow-cytometry histogram (right panel) (mean ± s.e.m., n=3, * 
P=0.0145, two-tailed paired t-test). (D) Relative mitochondrial mass of MV411 cells treated 
with AC220 1 nM or vehicle control (left panel) with representative flow-cytometry histogram 
(right panel) (mean ± s.e.m., n=3, ns, not significant, P=0.13, two-tailed paired t-test). (E) 
Relative GSH/GSSG ratio, GSH and GSSG of MV411 cells treated with AC220 1 nM or 
vehicle control (mean ± s.e.m., n=6, * P=0.0173, ns, not significant, two-tailed paired t-test). 
(F) Percentage of total levels of glutamine, glutamate, GSH and GSSG labelled by U-
13C5,15N2-GLN measured by LC-MS analysis in MV411 cells treated as in (A) (mean ± s.e.m., 
n=5, **** P<0.0001, ns, not significant, two-way ANOVA with Bonferroni’s multiple 
comparisons. (G) Relative GSH levels of MV411 cells treated with AC220 1 nM or vehicle 
control in the presence or absence of glutamine (mean ± s.e.m., n=5, ** P=0.0017, * 
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P=0.0471, q=4.248, DF=12, ANOVA with Tukey’s multiple comparisons). (H) Relative 
cytoplasmic ROS levels of MV411 cells treated with AC220 1 nM or vehicle control in the 
presence or absence of glutamine (mean ± s.e.m., n=14, **** P<0.0001, ANOVA with 
Tukey’s multiple comparisons). 
Figure 4: Rescue of combined effects of AC220 and CB839 by α-ketoglutarate  
(A-B) Oxygen consumption rate (OCR) in MV411 (A) and MOLM13 (B) cells treated with 
vehicle control, AC220 1 nM, CB839 100 nM, AC220 and CB839 combination and 
AC220/CB839 combination + 4 mM of dimethyl-α-ketoglutarate (αKG) measured using a 
Seahorse analyzer ( for MV411 mean ± s.e.m., n=3, for basal respiration ** P=0.0019 
between AC220 versus AC220+CB839, and P= 0.018 between AC220+CB839 versus 
AC220+CB839+αKG, for maximal respiration *** P=0.0002 between AC220 versus 
AC220+CB839, and  P=0.0224  between AC220+CB839 versus AC220+CB839+αKG, two-
way ANOVA with Bonferroni’s multiple comparisons; for MOLM13 cells mean ± s.e.m., n=3, 
for basal respiration * P=0.0298 between AC220 versus AC220+CB839, and P= 0.0182 
between AC220+CB839 versus AC220+CB839+αKG, for maximal respiration between * 
P=0.02 AC220 versus AC220+CB839, and  P=0.0148 between AC220+CB839 versus 
AC220+CB839+αKG, two-way ANOVA with Bonferroni’s multiple comparisons). (C-D) 
Relative cytoplasmic ROS levels of MV411 (C) and MOLM13 (D) cells treated as in (A-B) 
(for MV411 mean ± s.e.m., n=5, * P=0.0195, *** P=0.0008; for MOLM13 mean ± s.e.m., n=6, 
* P=0.0345, ANOVA with Tukey’s multiple comparisons). (E-F) Apoptosis in MV411 (E) and 
MOLM13 (F) cells treated as in (A-B) (for MV411 mean ± s.e.m., n=10, * P=0.0158 between 
AC220 versus AC220+CB839 and * P=0.0102 between AC220+CB839 versus 
AC220+CB839+αKG; for MOLM13 mean ± s.e.m., n=9, * P=0.0105 between AC220 versus 
AC220+CB839, and * P=0.0120 between AC220+CB839 versus AC220+CB839+αKG, 
ANOVA with Tukey’s multiple comparisons). 
Figure 5: Combined effects of tyrosine kinase inhibitors and CB839 in BCR-ABL 
positive leukemia 
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(A) Glycolytic rate and capacity of BCR-ABL mutated K562 cells treated with vehicle control 
or Imatinib 2 µM (mean ± s.e.m., n=3, P<0.0001 for both glycolytic rate and capacity, 
respectively, two-way ANOVA with Bonferroni’s multiple comparison) (B) Volcano plot for 
gene expression changes by RNA-sequencing of K562 cells treated with Imatinib 2 µM or 
vehicle control highlighting reduced expression of genes involved in glycolysis in treated 
cells (n=2). (C) q-PCR validation in K562 cells for the reduction in expression levels of 
GLUT3 (mean ± s.e.m., n=3, ** P=0.0081, two-tailed paired t-test) and LDHA (mean ± 
s.e.m., n=3, * P=0.0132, two-tailed paired t-test) following treatment as in (B). (D) Apoptosis 
in K562 cells treated with vehicle control, Imatinib 2 µM,  CB839 100 nM, Imatinib and 
CB839 combination and Imatinib/CB839 combination + 4 mM αKG (mean ± s.e.m., n=9, ** 
P=0.0019 between Imatinib versus Imatinib+CB839, and **** P<0.0001 between 
Imatinib+CB839 versus Imatinib+CB839+αKG, ANOVA with Tukey’s multiple comparisons) 
(E) Relative cytoplasmic ROS levels in BCR-ABL mutated K562 cells treated as in (D) (mean 
± s.e.m., n=6, * P=0.0495 between Imatinib versus Imatinib+CB839, and ** P=0.0089 
between Imatinib+CB839 versus Imatinib+CB839+αKG, ANOVA with Sidak’s multiple 
comparisons). (F) Oxygen consumption rate in K562 cells treated as in (D) (mean ± s.e.m., 
n=3, for basal respiration P=0.0606 between Imatinib versus Imatinib+CB839, and P<0.0001 
between Imatinib+CB839 versus Imatinib+CB839+aKG, for maximal respiration between **** 
P<0.0001 between both Imatinib versus Imatinib+CB839 and Imatinib+CB839 versus 
Imatinib+CB839+αKG, two-way ANOVA with Bonferroni’s multiple comparisons).  
Figure 6: Combined effects of AC220 and CB839 in FLT3ITD primary samples and in 
vivo 
(A) Extracellular acidification rate of primary FLT3ITD mutated AML samples treated with 
vehicle control or AC220 2.5 nM measured using a Seahorse analyzer (mean ± s.e.m., n=4, 
maximal glycolytic capacity **** P<0.0001, two-way ANOVA with Bonferroni’s multiple 
comparisons). (B) Oxygen consumption rate of primary FLT3ITD mutated AML samples 
treated with vehicle control, AC220 2.5nM, CB839 100 nM or their combination measured 
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using a Seahorse analyzer. Real-time basal and maximal respiration are shown and in the 
inset a bar charts for the basal respiration in the 4 different conditions is shown (mean ± 
s.e.m., n=4, ** P=0.0034 between AC220 versus AC220+CB839, ANOVA with Tukey’s 
multiple comparisons). (C) Relative viability in primary FLT3ITD mutated AML samples 
treated with vehicle control, AC220 2.5 nM, CB839 100 nM or their combination. Far left 
panel shows a summary plot for all 5 patients (mean ± s.e.m., n=5, ** P=0.0176 between 
AC220 versus AC220+CB839, ANOVA with Tukey’s multiple comparisons). The other 
panels show data for each individual patient with VAF (variant allele frequency) for FLT3ITD. 
Note in PT5 AC220 was used at 5 nM given low VAF for FLT3ITD. (D) Survival curve of mice 
transplanted respectively with MV411 transduced with control “Scramble” shRNA (n=9) and 
GLS shRNA (n=8) following treatment with AC220 (P=0.0030 by Log-rank test). (E-F) 
Percentage of RFP positive cells, measured by flow-cytometry, within 45 positive human 
cells from the bone marrow (E) and spleen (F) of mice transplanted respectively with MV411 
transduced with control “Scramble” shRNA (n=9) and GLS shRNA (n=8) following treatment 
with AC220 (box and whiskers showing minimum to maximum range * for bone marrow, 
P=0.0201; for spleen, **** P<0.0001, unpaired t test). (G) Schematic model showing the 
action mechanism of combined GLS and FLT3 TK inhibition. FLT3ITD mutant cells utilize both 
glucose and glutamine to support their metabolism (left panel). FLT3-TKI treatment (AC220) 
blocks glucose uptake and mostly glycolysis rendering the cells dependent on glutamine 
metabolism (middle panel). GLS gene silencing, chemical inhibition (CB839) or glutamine 
starvation enhance the efficacy of FLT3-TKI by blocking glutamine metabolism and its ability 
to support both TCA cycle/mitochondrial function and GSH synthesis/redox metabolism 
(right panel). 
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